6:29 PM
 | 
Nov 05, 2012
 |  BC Extra  |  Clinical News

Otsuka reports Phase III data for tolvaptan for kidney disease

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) said tolvaptan met the primary endpoint of slowing the annual rate of increase in total kidney volume vs. placebo over three years in the Phase III TEMPO 3:4 trial...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >